Baroldi Joseph 4

What Happened
Joseph Baroldi, Executive Vice President and Chief Business Officer of Ionis Pharmaceuticals (IONS), had 10,278 performance-based restricted stock units (PRSUs) vest on 2026-01-29 (awarded at $0.00) and sold 5,296 shares in open-market transactions on 2026-01-30 for a weighted average price of $82.96, totaling about $439,364. The vested PRSUs reflect a payout of 167.27% of target for a performance period tied to relative total shareholder return.

Key Details

• Transaction dates: Vesting/award 2026-01-29 (A); open-market sale 2026-01-30 (S). Filing date: 2026-02-02 (filed within standard reporting window).
• Sale price: weighted average $82.96; sales executed at prices ranging $82.95–$82.97 (multiple transactions). Total proceeds ≈ $439,364.
• Award details: PRSUs were for a 2023 grant; Compensation Committee certified performance at 167.27% of target (payout range originally 0%–200%).
• Shares owned after the transactions: Not specified in the excerpt provided.
• No 10b5-1 plan or tax-withholding sale code is disclosed in the provided filing; F2 notes the filer will provide a per-price breakdown on request.

Context
This filing shows a common sequence for executives: performance-based RSUs vested and a portion of shares was sold in the open market. The vesting was performance-driven (relative TSR vs. peers) and the sale generated roughly $439K in proceeds. The filing provides footnote detail on the performance certification and the exact sale price range.